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Celiac disease (CD) is one of the most common inflammatory diseases of the small intestine which causes abdominal pain, diar-
rhoea, malabsorption, weight loss, anorexia,  and iron deficiency anaemia in humans. It is a human leukocyte antigen (HLA)-
linked disorder that is triggered by the gluten and gliadin proteins from wheat and related cereals. The presence of other genetic 
factors such as HLA-DQ2 and HLA-DQ8 have also been identified for the generation of circulating autoantibodies to the en-
zyme transglutaminase (TG2). The TG2 enzyme deamidates the gluten peptides and increases their affinity for the HLA-DQ2 or 
HLA-DQ8, which in turn cause a more vigorous activation of CD4+ T-helper 1 (Th1) cells and trigger the immune response, and 
such immune cascade eventually leads to intestinal membrane damage and malabsorption. Generally, CD is managed by life-
long gluten-free diet. However, strict adherence to a gluten-free diet is difficult and is not always effective. Several pharmaco-
logical agents and alternative therapies for treating CD are currently under development and are in clinical trials, The purpose 
of this review is to highlight the complex involvement of genetics and immunity in CD and to focus on the novel strategies being 
used for developing adjunct and alternative therapies for the treatment of CD.. Biomed Rev 2014; 25: 45-58
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INTRODUCTION
Celiac disease (CD) is a one of the most common inflamma-
tory disease of the small intestine that is triggered in geneti-
cally predisposed individuals by gluten and gliadin proteins 
present in wheat, barley, and rye. CD manifests in various 
degrees ranging from intraepithelial lymphocytosis to severe 
subepithelial mononuclear cell infilteration resulting in total 
villous atrophy coupled with crypt hyperplasia. Through au-
toantibody and biopsy screening, the incidence of CD in the 
United States and other Western and Middle Eastern countries 
was found to be between 1:70 and 1:200 in human popula-
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tion (1-8). Celiac disease is often found in conjugation with 
other autoimmune disorders such as type-1 diabetes mellitus, 
autoimmune thyroiditis and dermatitis, herpetiformis and 
autoimmune alopecia (9). In addition, patients with long-
standing undetected or untreated symptomatic CD are likely 
to be at a higher risk of developing the enteropathy-associated 
with T-cell lymphoma, small bowel adenocarcinoma and 
other cancers of the gastrointestinal tract (10-13). Generally, 
CD is linked with major histocompatibility complex class II 
genes and the alleles encoding the human leukocyte antigen 
molecules HLA-DQ2 and HLA-DQ8 and almost all patients 
with CD carry these HLA alleles (14). However, CD has a 
multifactorial inheritance. Therefore, its occurrence not only 
depends on specific mutations of a single gene but also can 
be caused by a combination of environmental factors and 
variations in multiple genes (15, 16). Also the viral infections 
altering intestinal permeability, gut microbiota, breast-fed 
infants and timing of gluten introduction in infant’s diet has 
been implicated in the development of CD (17-19).
  While some environmental factors play a role in causing 
CD, gluten is one of the important players. Gluten-containing 
cereals have a high number of repetitive glutamine- and 
proline-rich sequences, thus making them highly resistant to 
proteolytic degradation by gastric, pancreatic, and intestinal 
brush-border enzymes, even in case of healthy individuals 
(20,21). Such proteolytic resistance results in the persistence 
of relatively large peptides in the gastrointestinal tract, which 
activate the small-bowel mucosal immune system, thereby 
leading to the development of CD in genetically predisposed 
individuals. Under normal physiological conditions, the 
intestinal epithelium is fairly impermeable to long peptides. 
However, in undiagnosed or untreated CD, the epithelial 
barrier function is compromised and gliadin peptides gain 
access across the epithelial layer and activate the immune 
system (22).
 Currently, the available treatment of CD is a lifelong strict 
gluten-free diet, which helps to relieve symptoms in most cases 
and effectively prevent the potential malabsorption problems 
(6, 23-29). However, it is difficult to maintain the gluten-free 
diet schedule and such practice can lead to social isolation, 
since modern diets are heavily based on gluten containing 
products. The lifelong strict gluten-free diet can also have 
an adverse impact on the quality of life of patients (30, 31). 
There are many instances where the gluten-free diet has been 
contaminated with wheat flour (32, 33). Owing to all these 
disadvantages and ineffectiveness of gluten-free diet in some 
cases, there is an increased need of alternative new therapeutic 
approaches. These novel therapies are being developed for the 
management of CD, based on the enhanced understanding of 
the pathogenic mechanisms that underline this disease.
ROLE OF GENETICS AND IMMUNITY IN CELIAC DISEASE
HLA class I and II genes map on the short arm of chromosome 
6 (6p21.3) and codes for the cell surface antigen presenting 
proteins and thus play a major role in immunity (34, 35). HLA 
class I heterodimers are constituted of alpha-heavy chain that 
encodes the HLA-A, B and C loci and by small beta 2-micro-
globulin molecule whose gene maps on chromosome 15. HLA 
class II heterodimers that consists of alpha and beta chains are 
specified by genes in the HLA-D region that comprehends 
HLA-DP (DPA1 and DPB1), DQ (DQA1 and DQB1) and DR 
(DRA1 and DRB1) genes (36).  Among the genetic markers, it 
is the HLA gene that seems to make greatest contribution to CD 
(37). The presence of the genes that are responsible for coding 
DQ2 and DQ8 molecules of HLA complex class II explains 
up to 40% of the occurrence of CD in European population 
(38). The association between DQ2 and DQ8 with CD is due 
to the high affinity of the DQ2 molecule of HLA towards the 
peptides- derived from gluten, which present them to the T 
lymphocytes (39). According to a multicenter study carried out 
in Europe, it was observed that the HLA DQ2 was present in 
about 86 to 93% of CD patients, while around 3 to 8% of these 
patients have DQ8 without DQ2 (40). Interestingly enough, 
these molecular markers are also carried by many individuals 
without CD, for example, in 40 to 65% of first degree relatives 
of CD patients and 18 to 30% of the normal population (41-43). 
Thus, CD has a multifactorial inheritance factors, and does 
not depend on the mutations of a single gene but it is caused 
by a combination of environmental factors and variations in 
multiple genes. In recent years, genome-wide association stud-
ies (GWAS) have identified many non-HLA genes associated 
with an increased risk of CD as indicated in Table 1, such as 
those coding for cytokines, chemokines and their receptors, 
cell adhesion molecules, T- and B-cell activators.
 The non-HLA genetic contribution to celiac disease is only 
15% and these polymorphisms are not considered in the calcu-
lation of the genetic risk (36).  The primary HLA-DQ associa-
tion in CD was initially confirmed by experiments on CD4+ 
T lymphocytes which were isolated from intestinal biopsies 
of patients who were able to recognize gluten peptides which 
were presented by DQ2.5/ DQ8 positive antigen presenting 
cells (60-63). The DQ2.5/DQ8 displays the highest affinity 
for the negatively charged amino-acids derived from the TG2 
mediated deamidation (i.e. conversion of glutamine to glutamic 
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Table 1. Non-HLA loci and genes of celiac disease susceptibility
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acid amino-acid) (64). This degree of affinity is dependent on 
the degree of interaction that occurs in the central region of 
nine amino-acid residues whose lateral positions are anchored 
to the positions P1, P4, P6, P7, and P9 into DQ-binding regions. 
Specifically, it is the DQ2.5 heterodimers that bind peptides 
with negatively charged side chains at P4, P6 and P7 positions 
while DQ8 molecules show only a preferential binding for 
the negatively charged residues at P1 and P9 (65). The role 
played by specific DQ heterodimers is being studied so as to 
understand the cause of the gluten-specific T-cell response in 
patients carrying other DQ molecules (not DQ2.5 or DQ8) 
(63, 66-68). Thus, it appears that the genetic predisposition 
to CD depends on one gene with a large effect (HLA-DQ2/
DQ8) on the adaptive immune response to gluten peptides 
and many other genes influencing different aspects of innate 
and adaptive immune reactions, intestinal permeability, and 
general predisposition to autoimmunity.
HLA MOLECULAR TYPING 
So far, only HLA-DQA1 and HLA-DQB1 loci can be used 
in the clinical practice of CD (69). By itself, HLA test does 
not have a diagnostic significance but is mainly considered 
for its negative predictive value since CD is highly unlikely 
to occur when DQ predisposing alleles are absent; while a 
positive result only means a genetic predisposition for celiac 
autoimmunity (36). Although many individuals carry DQ2.5/
DQ8 molecules but they do not depict the disease and only 
some will develop gluten intolerance. Thus, it is vital that 
future clinical investigations should address to identify new 
markers, which can improve prediction of the disease in people 
who carry the same HLA at-risk alleles.  Sequence Specific 
Primers-PCR, Reverse Dot Blot analysis and Real Time PCR 
have been used for HLA molecular typing, and recently, dif-
ferent commercial kits have been developed to specifically 
genotype CD-associated DQA1/DQB1 alleles (70, 71). Thus, 
HLA typing allows to define the CD risk gradient associated 
with each particular HLA-DQ status and DQB1*02 homo-
zygosity/heterozygosity (72, 73).  HLA typing is routinely 
suggested by clinicians in dubious CD case, i.e., uncertain 
or discrepant serology and or biopsy (74, 75). It is useful in 
screening first degree relatives due to the high prevalence of 
CD in first degree relatives.
 Almost all the patients with CD develop the immuno-
globulin (Ig) A autoantibodies to TG2 enzyme. The TG2 is 
responsible for deamidation of glutamine to negatively charged 
glutamic acid residues (76, 77). Due to their high content in 
glutamine and neighbouring proline and hydrophobic amino 
acid residues, gluten proteins, are substrates for TG2 (76, 78). 
When deamidated, the affinity of the negatively charged gluten 
peptides to HLA-DQ2 or HLA-DQ8 increases which results 
in a vigorous T-cell activation. While the adaptive immune 
response to gluten is well established, the gluten proteins can 
elicit an innate immune response in professional antigen-
presenting cells that activates predominantly the intraepithelial 
lymphocytes (IEL) but also the intestinal epithelial cells (79-
83). This innate immune response is an immediate reaction 
that appears to favour the development of adaptive immunity 
to gluten in patients who carry HLA-DQ2 or HLA-DQ8 (80). 
The innate immune activation of IELs by gluten induces the 
expression of the nonclassic class I molecule MICA on the 
intestinal epithelium which serves as a ligand for the heterodi-
meric NKG2D receptors.  
 It has been observed that epithelial MICA and up-regulated 
epithelial production of interleukin (IL)-15 leads to the activa-
tion of NKG2D on IELs (84). NKG2D also links the innate and 
adaptive immunity, because it triggers both antigen-specific 
lymphocyte mediated cytotoxicity and induces a direct cyto-
lytic function independent of T-cell receptor (TCR) specificity 
in effector CD8 T cells (85). The central role of IL-15 in the 
activation of innate and adaptive immunity in CD has been 
confirmed by several investigators (86-90), along with an 
increased expression of IL-15 receptor and a lower threshold 
for activation on IEL(88). Recently, it was found that IL-21, 
which is produced by CD4+ Th1 T-cells, has emerged as an 
additional driving force to the innate immunity that often 
acts in concert with IL-15 (91). It is imperative to know the 
pathogenesis of CD because it is one of the important causes 
of malabsorption in humans. The data analyses of a clinical 
study using endoscopic and histological features of 94 con-
secutive patients over 12 years indicated that CD is the most 
common cause of malabsorption followed by tropical sprue 
(92). According to this  study, 85.7% of the patients with 
tropical sprue had normal duodenal folds, whereas 82% of 
the patients with CD had abnormal duodenal folds. Also, the 
scalloping of folds as well as both scalloping and attenuation 
of the duodenal folds was more frequently present in patients 
with CD. On histological examination, it was observed that 
all the patients with CD had Marsh grade 3 villous atrophy, 
while only 11 patients with tropical sprue had Marsh grade 3 
villous atrophy. Crypt hyperplasia was greater in CD than that 
of tropical sprue.
 While increase in IELs were noted in all the biopsies, grade 
3 IEL infiltrates were seen only in CD. The extent of epithelial 
cell damage in the biopsies was focal in 85.7% of the patients 
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with tropical sprue, the extent of epithelial damage was mostly 
diffuse in those with CD. In addition, the normal tall columnar 
epithelium shape was maintained in most patients with tropical 
sprue, but changed from normal tall columnar epithelium to 
cuboidal cells in 40.9% of patients with CD (92). The marked 
histopathologal differences observed between CD and tropical 
spruce patients should be taken into consideration while ex-
amining the duodenal biopsy samples or doing the endoscopic 
examination of the GI tract. 
 Celiac Disease has numerous symptoms as indicated in 
Table 2. These symptoms vary with different people. These 
differences make the diagnosis of the disease difficult.





Diarrhoea Iron deficiency anaemia 
Weight loss Chronic pain
Abdominal pain Migraine
Anorexia Join pain/ inflammation









THE INTERVENTION OF NOVEL THERAPIES
As mentioned earlier, an efficient therapy for the patients suf-
fering from CD is ideally the adherence to a strict gluten- free 
diet, which is difficult to maintain and comply with. Such re-
striction may not only interfere with many social activities, but 
may also limit the enjoyment of food varieties. Furthermore, 
patients who have a high level of gluten sensitivity are likely 
to be adversely affected by even small amounts of gluten in 
their foods which may be declared gluten-free. Therefore, 
exploration of alternative therapies or adjunctive treatments 
becomes necessary for the CD patients. 
WHEAT VARIANTS AND GENETIC MODIFICATION 
Wheat strains with low immunogenicity, i.e., decreased num-
ber of immunogenic T-cell epitopes can be selected from the 
already existing varieties or from the genetically modified 
wheat. By hybridization between tetraploid Triticum turgi-
dum and the diploid Triticum tauschii, the hexaploid Triticum 
aestivum was generated. The tetraploid Triticum turgidum 
likely originated from the diploid Triticum monococcum and 
Triticum speltoides (94). The duodenal biopsy specimens from 
patients with celiac disease showed that ingestion of tetraploid 
wheat gluten caused reduced toxicity as opposed to the intake 
of hexaploid wheat (95). Similarly two other wheat varieties, 
one low in α- and β-gliadins and another low in α-, β-, γ- and 
ω-gliadins also showed  decreased toxicity in duodenal biopsy 
specimens (96). 
     With the utilization of gluten-specific T-cell clones from 
duodenal biopsy specimens of CD patients and the identi-
fication of key immunogenic T-cell epitopes, including the 
antibodies directed to some of these epitopes, provided re-
producible results for the characterization of less toxic wheat 
species. In silico approach was applied to analyze 230 α-gliadin 
sequences derived from ancestral halotypes for the presence 
of T-cell stimulatory epitopes that bind to HLA-DQ2/8. It 
was observed that all major immunogenic peptides are pres-
ent in the DD genotype, except for α-9 sequences in the AA 
genotype. The gluten digest from T. tauschii which contains 
the α-gliadin sequences that is encoded by the DD genome 
elicited the strongest T-cell response as compared to the gluten 
derived from the AA and BB genome species that lack these 
sequences were dampened (97, 98).
   Genetic deletion of certain gliadin genes was analyzed in 
T. aestivum, which lacks one locus containing gluten genes. 
This was carried out by in silico analysis based on the known 
DNA sequences and by Western blotting with epitope specific 
antibodies (99). The results revealed that the complete deletion 
of the α-gliadin locus on chromosome 6 led to a decrease in 
total T-cell stimulatory epitopes, however, it also impaired the 
baking properties of this wheat variety. 
PRETREATMENT OF FLOURS AND GERMINATION OF WHEAT
Certain lactobacilli added to sourdough for fermentation are 
able to proteolyze the proline- or glutamine-rich gluten pep-
tides and thus decrease the immunotoxicity (100-102). A pilot 
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study done in 17 CD patients suggested that the sourdough 
bread was well tolerated. Since the patients were challenged 
only for 2 days, hence it was difficult to draw any definitive 
conclusions from this very short period study (103). In a similar 
manner, intrinsic proteases are produced during germination 
of wheat, i.e., when the amino acids from the gluten storage 
proteins are being used by the growing plant. The germination 
process of wheat can degrade the immunogenic T-cell epitopes, 
and thus create nontoxic cereal product for patients suffering 
from CD (104). Another alternative would be to inactivate 
immunogenic gluten epitopes by exploiting the substrate 
specificity of TG2 that generates more potent gluten peptides 
via deamidation (105).
 The treatment of wheat with low molecular weight micro-
bial TG, derived from Streptomyces moboraensis, reduced 
the stimulatory effect of the flour on gluten reactive T-cells. 
Additionally, treatment of TG with these microbes improves 
loaf volume and crumb texture of breads (106). Neverthe-
less, caution is necessary since the treatment of flour with the 
microbial TG increased rather than decreasing the stimulation 
of gliadin-specific T-cells (107, 108). Thus, the future studies 
should focus on the development of cereals that are devoid 
of immunogenic epitopes along with conserving their baking 
qualities.
ORAL ENZYME THERAPY 
 Usually the complex proteins that reach the intestinal lu-
men are digested by gastric pepsin and pancreatic proteases 
and further degraded by the brush border enzymes into the 
simpler amino acids, dipeptides or tripeptides that are trans-
ported across the epithelial layer. The large quantity of proline 
residues in immunodominant gliadin peptides which make 
them highly resistant to the human digestive proteases (109-
111). Hence, in order to avoid those peptides from reaching 
the lamina propria, prolyl-endopeptidases (PEP) which are 
expressed in many microorganisms were used to cleave the 
immunodominant proline rich regions (112-116). A study was 
performed using PEP obtained from Flavobacterium meningo-
septicum admixed to a daily drink with 5 grams of gluten over 
2 weeks, and it could prevent fat malabsorption and symptoms 
in some patients with previously diet controlled CD (117). 
However, the potency of the enzyme was not considered suf-
ficient enough to draw any clear conclusions. The PEP from 
Aspergillus niger, which has a higher specific activity than 
PEP from Flavobacterium meningosepticum to inactivate the 
immunodominant gluten peptides may be tried (118, 119). 
INHIBITION OF INTESTINAL PERMEABILITY 
In healthy individuals, the tight junctions between the epithelial 
cells protect and control the exposure of the submucosal gas-
trointestinal tissues to the macromolecules which may be toxic. 
However, in patients with CD there is an increased intestinal 
permeability due to the opening of the tight junctions (zonulae 
occludentes), causing an increased influx of the gluten peptides 
into the subepithelial lamina propria and the T-cell response 
to gluten is triggered. Previous studies identified that the hu-
man protein zonulin, a precursor of prehaptoglobin-2, acts as 
a regulator of epithelial permeability and is highly expressed 
in CD and is likely a contributor to its pathology (120,121). 
This protein is similar in effect to that of zonula occludens 
toxin (ZOT) expressed by Vibrio cholerae, which impairs epi-
thelial tight junctions integrity (122). An octapeptide derived 
from ZOT (AT-1001) antagonises zonulin action via receptor 
blockade and thus protects tight junctional integrity (123). A 
pilot study was performed using AT-1001 in 14 patients with 
CD in remission and 7 controls who were challenged with a 
single dose of gluten for three consecutive days, and it was 
observed that the intestinal permeability remained intact (124). 
It appears that a complementary therapeutic approach and its 
combination with other treatments could be more effective for 
treating CD patients.
TRANSGLUTAMINASE-2 INHIBITORS 
The use of transglutaminase-2 (TG-2) inhibitors is also one 
of the novel therapy because inhibiting the deamidation of 
the gliadin peptide decreases its affinity to HLA-DQ2 and 
HLA-DQ8 and consecutively decreases the T-cell stimulation. 
Many inhibitors that target the transglutaminase cross-linking 
activity have been developed and tested in vitro (125-128). 
There are several competitive inhibitors of TG-2 (putrescine, 
spermidine, histamine, monodansyl cadaverin, cadaverine, 
5-pentylamine, fluoresceine, cystamine and cysteamine) 
(129); reversible inhibitors (mainly guanoside triphosphate 
analogues) (130) and irreversible inhibitors (iodoacetamide, 
3-halo-4,5-dihydroisoxazoles, carbobenzyloxy-L-glutaminyl 
glycine derivatives, 6-diazo-5-oxo-norleucine, 2-[(2-oxo-
propyl)thio]imidazolium derivatives) (131,132). Cystamine 
and 2-[(2-oxopropyl)thio]imidazolium inhibitors (L682777 
or R283) have also been tested ex vivo in cultures of small 
intestinal biopsy specimens of patients with CD where there 
was a decrease in the T-cell stimulatory activity of gliadin 
peptides (133,134). However, this therapeutic approach is 
risky, since transglutaminase plays many important roles in 
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the body and the inhibitory agents have to be designed so that 
they specifically remain in the intestine and do not cross to the 
systemic circulation. 
HLA-DQ2 INHIBITORS 
Adaptive immunity in CD is activated due to the binding of 
the gliadin peptides onto the HLA-DQ2, thus blocking the 
DQ2 as an attractive target to prevent the immune activation. 
Modification of α- gliadin so as to make it a partial agonist, 
significantly inhibited the IFN-γ production as compared to 
the patients with CD having the unmodified peptide (135). 
Furthermore, replacement of leucine L11 and L18 residues in 
the α-gliadin with sterically bulky groups retained the DQ2 
affinity but decreased the T-cell recognition (136). Overall, if 
the designed inhibitors act locally in the gut and specific for 
gluten, it could constitute a potential therapeutic approach.
ANTI-INFLAMMATORY COMPOUNDS 
 One characteristic feature of  CD  is persistent inflammation of 
the intestinal tract. Treatment with corticosteroids and immu-
nosuppressive agents have been considered. In a cohort study 
of 30 people, a combination of gluten-free diet and corticoste-
roids was found to be effective in treating the symptoms and 
healing of mucosal injury (137). Budesonide, a locally acting 
corticosteroid with minimal side effects when used in addition 
with gluten-free diet significantly improved the malabsorption 
symptoms (138). There also has been a report of mesalamine 
to treat the refractory sprue patients (139).
IL-15 ANTAGONISTS
An increased expression of IL-15 is responsible for the de-
velopment of refractory CD, since it induces the secretion of 
epithelial MICA that binds to NKG2D receptor located on the 
surface of intraepithelial lymphocytes. A study on transgenic 
mouse models with overexpression of IL-15 and consequent 
development of autoimmune enteropathy indicates that block-
ing antibody against IL-15 was capable of efficiently reversing 
the intestinal damage (140, 141). IL-15 blocking antibodies 
were able to decrease the number of intraepithelial lympho-
cytes that accumulated in the intestinal epithelium of human 
IL-15 transgenic mouse models (142).
CXCL10 AND CXCR3
It was found that the CXCL10 which is another T-cell recruit-
ing chemokine that elicits its effects by binding to the receptor 
CXCR3 expressed by T-lymphocyte showed an increased 
expression in response to the gliadin stimulation of monocytes 
(143). These findings support the role of T cell-recruiting 
chemokines as a future therapeutic target not only for CD but 
also for gluten sensitivity in general (144).
CONCLUSIONS
In humans, CD is a leukocyte antigen (HLA)-linked disorder 
that is triggered by the gluten and gliadin proteins present 
in wheat, rye and barley. It appears that early humans didn’t 
eat cereal grains, so people didn’t evolve the ability to break 
down and digest gluten. Thus, in some subjects the body treats 
gluten as a toxin that triggers gut reactions. Globally, increased 
number of patients are diagnosed with CD. This chronic in-
flammatory disease of the small intestine causes abdominal 
pain, diarrhoea, malabsorption, weight loss, anorexia, and iron 
deficiency anaemia. 
 Due to better understanding of the underlying pathol-
ogy, there has been a development of adjunctive and even 
alternative therapeutic approaches that help effectively 
to manage or even cure this condition. Although several 
pharmacological agents for treating CD are currently under 
development and are in clinical trials, gluten-free diet still 
remains the only treatment option for these patients, who 
regardless of the social aspect lack any significant or poten-
tially life threatening side effects. Therefore, in addition to 
therapeutic efficacy for reducing both CD symptoms and 
histological intestinal damage, the ideal alternative therapy 
to lifelong gluten withdrawal will need development of safe 
and efficacious products. This encouraging trend could gain 
momentum in the coming years.
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